Business
Dogwood Therapeutics Announces Enrollment of First Fifty Patients in Ongoing Halneuron® Phase 2b Trial
- Halneuron® Chemotherapy-Induced Neuropathic Pain (“CINP”) Phase 2b study interim data readout remains on track as projected for Q4 2025 - - Low discontinuation rate (6%) due to adverse events amongst the first 35 patients completing the trial suggests Halneuron® and placebo treatment have been generally well tolerated - ATLANTA, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biotechnology company developing new medicines to trea
About this update from Dogwood Therapeutics, Inc.
[{"type":"image","alt":"Dogwood Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Dogwood Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/31af9905c689ad6d0133d00b8d554d8f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ymONq2rYrZZXJkVRmE8SRQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/31af9905c689ad6d0133d00b8d554d8f","width":300,"height":300}},"lazy":false},{"type":"text","content":"- Halneuron® Chemotherapy-Induced Neuropathic Pain (“CINP”) Phase 2b study interim data readout remains on track as projected for Q4 2025 -","length":139,"tagName":"p"},{"type":"text","content":"- Low discontinuation rate (6%) due to adverse events amongst the first 35 patients completing the trial suggests Halneuron® and placebo treatment have been generally well tolerated -","length":183,"tagName":"p"},{"type":"text","content":"ATLANTA, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biotechnology company developing new medicines to treat pain and fatigue-related disorders, today announced it has enrolled the first 50 patients in its ongoing Phase 2b CINP trial and remains on track to execute its planned interim analysis on approximately 100 patients who will have completed the four week trial during the fourth quarter of this year.","length":477,"tagName":"p"},{"type":"text","content":"“There has been increasing interest in the role of Nav 1.7 and Nav 1.8 sodium channel inhibition as alternatives for pain treatment over the past few years,” said Greg Duncan, Chief Executive Officer of Dogwood Therapeutics. “We believe the novelty of Halneuron’s® specificity and potency for Nav 1.7 sodium channel inhibition, as well as the uniqueness of the cancer and chemotherapy related neuropathic pain disease targets differentiates our program from other sodium channel research programs.”","length":498,"tagName":"p"},{"type":"text","content":"“Positive data from prior Halneuron® cancer pain and CINP clinical trials underpins both patient and research community interest in participating in this landmark study,” said Michael Gendreau, MD, PhD, Chief Medical Officer of Dogwood Therapeutics. “Based on this interest, we continue to add qualified r...